Silexion Therapeutics Statistics
 Total Valuation
 SLXN has a market cap or net worth of $1.85 million. The enterprise value is $5.16 million.
 Important Dates
 The next estimated earnings date is Wednesday, November 12, 2025, before market open.
 | Earnings Date | Nov 12, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 SLXN has 560,974 shares outstanding.
 | Current Share Class | 560,974 | 
| Shares Outstanding | 560,974 | 
| Shares Change (YoY) | n/a | 
| Shares Change (QoQ) | +150.35% | 
| Owned by Insiders (%) | n/a | 
| Owned by Institutions (%) | 7.69% | 
| Float | 429,724 | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | n/a | 
| Forward PS | n/a | 
| PB Ratio | n/a | 
| P/TBV Ratio | n/a | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | n/a | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 0.64
 | Current Ratio | 0.64 | 
| Quick Ratio | 0.34 | 
| Debt / Equity | n/a | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | -465.59 | 
Financial Efficiency
  | Return on Equity (ROE) | n/a | 
| Return on Assets (ROA) | -193.54% | 
| Return on Invested Capital (ROIC) | -427.70% | 
| Return on Capital Employed (ROCE) | 1,904.70% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | -$1.17M | 
| Employee Count | 14 | 
| Asset Turnover | n/a | 
| Inventory Turnover | n/a | 
Taxes
 In the past 12 months, SLXN has paid $10,000 in taxes.
 | Income Tax | 10,000 | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has decreased by -91.74% in the last 52 weeks. The beta is -0.07, so SLXN's price volatility has been lower than the market average.
 | Beta (5Y) | -0.07 | 
| 52-Week Price Change | -91.74% | 
| 50-Day Moving Average | 4.57 | 
| 200-Day Moving Average | 12.00 | 
| Relative Strength Index (RSI) | 32.67 | 
| Average Volume (20 Days) | 79,010 | 
Short Selling Information
 The latest short interest is 152,730, so 27.23% of the outstanding shares have been sold short.
 | Short Interest | 152,730 | 
| Short Previous Month | 28,888 | 
| Short % of Shares Out | 27.23% | 
| Short % of Float | 35.54% | 
| Short Ratio (days to cover) | 0.37 | 
Income Statement
  | Revenue | n/a | 
| Gross Profit | n/a | 
| Operating Income | -12.57M | 
| Pretax Income | -16.51M | 
| Net Income | -16.44M | 
| EBITDA | -12.55M | 
| EBIT | -12.57M | 
| Earnings Per Share (EPS) | -$395.36 | 
 Full Income StatementBalance Sheet
 The company has $1.19 million in cash and $4.49 million in debt, giving a net cash position of -$3.30 million or -$5.89 per share.
 | Cash & Cash Equivalents | 1.19M | 
| Total Debt | 4.49M | 
| Net Cash | -3.30M | 
| Net Cash Per Share | -$5.89 | 
| Equity (Book Value) | -3.99M | 
| Book Value Per Share | -32.37 | 
| Working Capital | -1.27M | 
 Full Balance SheetCash Flow
 In the last 12 months, operating cash flow was -$8.40 million and capital expenditures -$22,000, giving a free cash flow of -$8.42 million.
 | Operating Cash Flow | -8.40M | 
| Capital Expenditures | -22,000 | 
| Free Cash Flow | -8.42M | 
| FCF Per Share | -$15.01 | 
 Full Cash Flow StatementMargins
  | Gross Margin | n/a | 
| Operating Margin | n/a | 
| Pretax Margin | n/a | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 SLXN does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | n/a | 
| Shareholder Yield | n/a | 
| Earnings Yield | -888.23% | 
| FCF Yield | -454.73% | 
 Analyst Forecast
 The average price target for SLXN is $75.00, which is 2,172.73% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $75.00 | 
| Price Target Difference | 2,172.73% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 1 | 
| Revenue Growth Forecast (5Y) | n/a | 
| EPS Growth Forecast (5Y) | -57.15% | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 The last stock split was on July 29, 2025. It was a reverse split with a ratio of 1:15.
 | Last Split Date | Jul 29, 2025 | 
| Split Type | Reverse | 
| Split Ratio | 1:15 | 
Scores
  | Altman Z-Score | n/a | 
| Piotroski F-Score | 1 |